Victoria Johnson

Researchers from Massachusetts General Hospital found that DMT-treated patients were, on average, younger than untreated patients.

Researchers from the University of Washington Medical Center analyzed data from almost 10,000 infusions of natalizumab.

Researchers investigated the test, which is normally used to differentiate people with MS from healthy controls, in a population of those with multiple sclerosis.

The trial of anakinra is underway, while the trial for tolebrutinib is undergoing regulatory review.

Researchers retrospectively analyzed patient follow-ups and found that 50% of patients were ultimately diagnosed with multiple sclerosis.

Similar proportions of both in-clinic and telemedicine patients had modified Rankin scale score improvements.

A recent study investigated self-reported outcomes of preventive treatment prior to the introduction of calcitonin gene related peptide (CGRP) receptor targeting.

Bijan Nejadnik, MD, chief medical officer, SanBio, also thanked neurological experts that collaborated on the phase 2 STEMTRA trial.

Researchers also found that during the COVID-19 pandemic, there were reduced rates of stroke quality of care measures.

Racial disparities in biomarkers highlight the need to investigate different populations in trials of Alzheimer disease.

Masahito Kawabori, MD, PhD, associate professor, Hokkaido University, discussed results of the phase 2 STEMTRA trial.

Jennifer Martin, PhD, AASM board of directors' member and professor of medicine at UCLA discussed CBI-T and some of the challenges in treating patients with chronic insomnia.

Researchers also found that patients treated with autologous hematopoietic stem cell transplantation had higher rates of infection then other DMT-treated groups.

Alector’s announcement about the INVOKE-2 study follows a similar update regarding its INFRONT-3 study for frontotemporal dementia.

The neurologist from Cleveland Clinic discussed how patients with early-onset NMOSD were more likely to have severe residual vision loss.

The Biomodex-developed models have also been studied in pre-procedural rehearsal for brain aneurysms.

Researchers found that 93% of patients with AS exhibited dystonia in their limbs, mouth, neck, or trunk.

Both therapeutic programs utilize AAD2-GDNF gene therapy targeted to brain structures vulnerable to Parkinson disease and multiple system atrophy.

Researchers found that infantile epileptic encephalopathy and SEI with migrating focal seizures had the highest mortality rates at 2 years of age.

Mini-mental state exam scores declined significantly faster in adults with prevalent and incident epilepsy, while digit symbol substitution test scores declined significantly faster in prevalent epilepsy.

Socioeconomic deprivation was associated with IIH independently of BMI in women but not men.

The treatment can be used in children who do not respond well to anticholinergic medications.

While patients with relapsing-remitting MS were found to benefit more from aHSCT, patients with progressive MS still experienced stability in disability scores.

Despite significant improvements in Dravet syndrome, non-statistically significant reductions were observed in children with Lennox-Gastaut Syndrome.

The chief scientific officer of QurAlis discussed how QRA-244 is more specific and potent than retigabine, a treatment currently in clinical studies.

Researchers compared CMH rates in PSEN1, PSEN2, and APP mutation carriers and noncarriers of dominantly inherited Alzheimer disease.

Researchers also observed that PAP machines from ISPs were used for a longer median duration than those from DMEs.

Researchers found that time between assessments was the only predictor of PACC score differences.

A score based on these variables was found to show good discrimination and calibration in predicting early neurological deterioration of ischemic origin, or ENDi.

The results suggest that BACE-1 inhibitors, while a promising option to slow progression of Alzheimer disease, require further study with careful safety monitoring.